Why is Mangalam Drugs falling/rising?

As of 24-Sep, Mangalam Drugs and Organics Ltd is experiencing a decline in its stock price, currently at 74.11, reflecting a decrease of 0.93 or 1.24%. The stock has underperformed its sector by 0.79% today and has been on a downward trend for the last three days, accumulating a total loss of 2.35%. Over the past month, the stock has seen a significant drop of 7.43%, and its year-to-date performance shows a staggering decline of 36.08%. The company's financial health is concerning, as it has reported operating losses and a substantial fall in net sales by 21.48%. Additionally, the stock is trading below all its moving averages, indicating a bearish trend, and investor participation has decreased sharply, with delivery volume falling by 45.67% compared to the five-day average.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has underperformed the Sensex, which has gained 0.50% over the past month. This consistent underperformance is highlighted by the stock's returns of -41.65% over the past year, compared to the Sensex's decline of only 3.77%. The company's weak long-term fundamentals, including a poor EBIT to interest ratio and negative profit growth, further exacerbate its challenges. Despite having a relatively attractive valuation compared to peers, the ongoing operational losses and negative results over consecutive quarters have led to a lack of investor confidence, contributing to the stock's downward trajectory.